Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.

By M. Konstam, M. Gheorghiade, J. Burnett, L. Grinfeld, A. Maggioni, K. Swedberg, J. Udelson, F. Zannad, T. Cook, J. Ouyang and 2 more. Journal of the American Medical Association (JAMA), 2007

1,662 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/ba0503877e1d1d6a879a3d0a6d7e0df7d4b03c41

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Gerasimos Filippatos
2. M. Gheorghiade
3. M. Flemmer
4. P. Marik
5. J. Udelson
6. S. Anker
7. M. Drazner
8. D. Avers

In Surgery

1. P. Marik

Citations in the corpus

• Acute heart failure syndromes (2009, background): “Continuation of fixed doses of A olvaptan after discharge decreased neither mortality nor eadmission rates, in spite of a reduction in BW when ompared with standard therapies (60,107).”
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡ (2008, neutral): “In EVEREST, tolvaptan relieved symptoms associated with AHF and promoted weight loss in the acute phase, but did not reduce mortality or morbidity at 1 year.(227)”
• Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. (2007, methodology): “The combined long-term safety profile for the entire population is presented in the companion article for the EVEREST long-term outcome study.(17) An overall in-hospital mortality rate of 2.”
• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, neutral): “tachycardia-induced cardiomyopathy (154).”
• Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine (2010, result): “placebo in patients hospitalized with worsening HF and LV ejection fraction (LVEF) ≤40%, demonstrated a significant reduction in symptoms of congestion due to loss in body fluid with tolvaptan; however, mortality and hospitalizations were unaffected when compared with placebo.(45,46) Moreover, a dru”
• Narrative Review (2012, background): “Although these agents are associated with a greater net fluid loss than placebo and normalization of the serum sodium, they have not been associated with improved clinical outcomes.(97)”